Piper Sandler analyst David Amsellem raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q3 net earnings per share of 0c on total revenues of $74.4M, compared to Street estimates of 1c and $74.2M, respectively. Notably, Recorlev continues to benefit from an expanding hypercortisolism space, positioning the company for sustainable cash generation, Piper adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Pharmaceuticals: Strong Growth Potential and First Profitable Quarter Drive Buy Rating
- Xeris Biopharma Reports Strong Q3 2025 Financial Results
- Xeris Biopharma Reports Record Revenue Growth in Earnings Call
- Xeris Biopharma reports Q3 EPS 0c, consensus 0c
- Xeris Biopharma price target raised to $18 from $8 at Oppenheimer